Literature DB >> 2981135

Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy.

R A Hegele, A Angel.   

Abstract

A 16-year-old girl, one of dizygotic twins, presented in 1976 complaining of a 1-year history of a lack of coordination and an inability to run. The results of biochemical tests confirmed the diagnosis of classic abetalipoproteinemia. In addition to the recognized neurologic features of this disorder, she had a reduced evoked motor unit potential and markedly elevated serum levels of muscle enzymes, which suggested myositis. The serum vitamin E level was markedly decreased. Oral therapy with vitamin E, 800 mg daily, was begun, and in 1981 the dosage was increased to 3200 mg daily. Over the 7 years of follow-up she improved clinically, there was an increase in the evoked motor unit potential, the serum levels of some of the muscle enzymes decreased to normal, and the serum and tissue vitamin E levels increased significantly. It was concluded that treatment with high doses of vitamin E was responsible for the arrest of the usually progressive neuropathy and myopathy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981135      PMCID: PMC1346503     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  17 in total

Review 1.  The biological function of vitamin E and the nature of the interaction of the vitamin with selenium.

Authors:  A T Diplock
Journal:  World Rev Nutr Diet       Date:  1978       Impact factor: 0.575

2.  Progressive neuropathologic lesions in vitamin E-deficient rhesus monkeys.

Authors:  J S Nelson; C D Fitch; V W Fischer; G O Broun; A C Chou
Journal:  J Neuropathol Exp Neurol       Date:  1981-03       Impact factor: 3.685

3.  Effect of large oral doses of vitamin E on the neurological sequelae of patients with abetalipoproteinemia.

Authors:  D P Muller; J K Lloyd
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

4.  Association of spinocerebellar disorders with cystic fibrosis or chronic childhood cholestasis and very low serum vitamin E.

Authors:  E Elias; D P Muller; J Scott
Journal:  Lancet       Date:  1981-12-12       Impact factor: 79.321

5.  A progressive neurologic syndrome in children with chronic liver disease.

Authors:  J L Rosenblum; J P Keating; A L Prensky; J S Nelson
Journal:  N Engl J Med       Date:  1981-02-26       Impact factor: 91.245

6.  Reversibility of human myopathy caused by vitamin E deficiency.

Authors:  L G Tomasi
Journal:  Neurology       Date:  1979-08       Impact factor: 9.910

7.  The neuropathy of abetalipoproteinemia.

Authors:  R G Miller; C J Davis; D R Illingworth; W Bradley
Journal:  Neurology       Date:  1980-12       Impact factor: 9.910

8.  Abetalipoproteinemia. Report of two cases and review of therapy.

Authors:  D R Illingworth; W E Connor; R G Miller
Journal:  Arch Neurol       Date:  1980-10

9.  Abetalipoproteinemia treated with parenteral and oral vitamins A and E, and with medium chain triglycerides.

Authors:  E Azizi; J L Zaidman; J Eshchar; A Szeinberg
Journal:  Acta Paediatr Scand       Date:  1978-11

10.  Axonal dystrophy in the gracile nucleus in congenital biliary atresia and cystic fibrosis (mucoviscidosis): beneficial effect of vitamin E therapy.

Authors:  J H Sung; S H Park; A R Mastri; W J Warwick
Journal:  J Neuropathol Exp Neurol       Date:  1980-09       Impact factor: 3.685

View more
  16 in total

1.  Importance of screening the peripheral smear.

Authors:  Sarala Rajajee; Malathi Sathyasekaran; Janani Shankar; Latha Dhathathri
Journal:  Indian J Pediatr       Date:  2002-09       Impact factor: 1.967

2.  Characterization of high density lipoprotein binding to human adipocyte plasma membranes.

Authors:  B S Fong; P O Rodrigues; A M Salter; B P Yip; J P Despres; A Angel; R E Gregg
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

3.  Epitopes of apolipoprotein B-100 and B-48 in both liver and intestine. Expression and evidence for local synthesis in recessive abetalipoproteinemia.

Authors:  R P Dullaart; B Speelberg; H J Schuurman; R W Milne; L M Havekes; Y L Marcel; H J Geuze; M M Hulshof; D W Erkelens
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

Review 4.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

Review 5.  Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management.

Authors:  Jooho Lee; Robert A Hegele
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

Review 6.  Vitamin E--its role in neurological function.

Authors:  D P Muller
Journal:  Postgrad Med J       Date:  1986-02       Impact factor: 2.401

7.  Abetalipoproteinaemia in adults: role of vitamin therapy.

Authors:  A J MacGilchrist; P R Mills; M Noble; W S Foulds; J A Simpson; G Watkinson
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 8.  Interactions between α-tocopherol, polyunsaturated fatty acids, and lipoxygenases during embryogenesis.

Authors:  Katie M Lebold; Maret G Traber
Journal:  Free Radic Biol Med       Date:  2013-08-03       Impact factor: 7.376

Review 9.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

Review 10.  Dosage and formulation issues: oral vitamin E therapy in children.

Authors:  Tone Westergren; Betty Kalikstad
Journal:  Eur J Clin Pharmacol       Date:  2009-10-13       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.